NAD+-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin

Conclusions: The findings from this research for the first time demonstrate that NAD+-boosting therapy reverses NAFLD by regulating SIRT2-deppendent Fndc5 deacetylation and deubiquitination, which results in a stimulation of Fndc5/irisin, a novel exerkine. These results suggest that Fndc5/irisin may be a potential nexus between physical exercise and NAD+-boosting therapy in metabolic pathophysiology.

Source: Theranostics - April 19, 2021 Category: Molecular Biology Authors: Dong-Jie Li, Si-Jia Sun, Jiang-Tao Fu, Shen-Xi Ouyang, Qin-Jie Zhao, Li Su, Qing-Xi Ji, Di-Ynag Sun, Jia-Hui Zhu, Guo-Yan Zhang, Jia-Wei Ma, Xiu-Ting Lan, Yi Zhao, Jie Tong, Guo-Qiang Li, Fu-Ming Shen, Pei Wang Tags: Research Paper Source Type: research